1484 related articles for article (PubMed ID: 32631826)
21. A Randomized Clinical Trial of the Efficacy and Safety of Interferon β-1a in Treatment of Severe COVID-19.
Davoudi-Monfared E; Rahmani H; Khalili H; Hajiabdolbaghi M; Salehi M; Abbasian L; Kazemzadeh H; Yekaninejad MS
Antimicrob Agents Chemother; 2020 Aug; 64(9):. PubMed ID: 32661006
[TBL] [Abstract][Full Text] [Related]
22. Potential therapeutic agents against COVID-19: What we know so far.
Lu CC; Chen MY; Lee WS; Chang YL
J Chin Med Assoc; 2020 Jun; 83(6):534-536. PubMed ID: 32243270
[TBL] [Abstract][Full Text] [Related]
23. Effect of Systemic Inflammatory Response to SARS-CoV-2 on Lopinavir and Hydroxychloroquine Plasma Concentrations.
Marzolini C; Stader F; Stoeckle M; Franzeck F; Egli A; Bassetti S; Hollinger A; Osthoff M; Weisser M; Gebhard CE; Baettig V; Geenen J; Khanna N; Tschudin-Sutter S; Mueller D; Hirsch HH; Battegay M; Sendi P
Antimicrob Agents Chemother; 2020 Aug; 64(9):. PubMed ID: 32641296
[TBL] [Abstract][Full Text] [Related]
24. Remdesivir against COVID-19 and Other Viral Diseases.
Malin JJ; Suárez I; Priesner V; Fätkenheuer G; Rybniker J
Clin Microbiol Rev; 2020 Dec; 34(1):. PubMed ID: 33055231
[TBL] [Abstract][Full Text] [Related]
25. SARS-CoV-2: Recent Reports on Antiviral Therapies Based on Lopinavir/Ritonavir, Darunavir/Umifenovir, Hydroxychloroquine, Remdesivir, Favipiravir and other Drugs for the Treatment of the New Coronavirus.
Costanzo M; De Giglio MAR; Roviello GN
Curr Med Chem; 2020; 27(27):4536-4541. PubMed ID: 32297571
[TBL] [Abstract][Full Text] [Related]
26. Lopinavir/ritonavir for the treatment of SARS, MERS and COVID-19: a systematic review.
Vargas M; Servillo G; Einav S
Eur Rev Med Pharmacol Sci; 2020 Aug; 24(16):8592-8605. PubMed ID: 32894567
[TBL] [Abstract][Full Text] [Related]
27. Treatment of SARS-CoV-2: How far have we reached?
Ahsan W; Javed S; Bratty MA; Alhazmi HA; Najmi A
Drug Discov Ther; 2020 May; 14(2):67-72. PubMed ID: 32336723
[TBL] [Abstract][Full Text] [Related]
28. COVID-19: Review on latest available drugs and therapies against SARS-CoV-2. Coagulation and inflammation cross-talking.
Magro G
Virus Res; 2020 Sep; 286():198070. PubMed ID: 32569708
[TBL] [Abstract][Full Text] [Related]
29. Lopinavir/ritonavir did not shorten the duration of SARS CoV-2 shedding in patients with mild pneumonia in Taiwan.
Cheng CY; Lee YL; Chen CP; Lin YC; Liu CE; Liao CH; Cheng SH
J Microbiol Immunol Infect; 2020 Jun; 53(3):488-492. PubMed ID: 32331982
[TBL] [Abstract][Full Text] [Related]
30. Rigorous Randomized Controlled Trial Implementation in the Era of COVID-19.
Oldenburg CE; Doan T
Am J Trop Med Hyg; 2020 Jun; 102(6):1154-1155. PubMed ID: 32297590
[No Abstract] [Full Text] [Related]
31. Some drugs for COVID-19.
Med Lett Drugs Ther; 2020 Apr; 62(1595):49-50. PubMed ID: 32324177
[No Abstract] [Full Text] [Related]
32. A Case of Breakthrough COVID-19 during Hydroxychloroquine Maintenance.
Ahn BY; Kang CK; Seo JD; Choe PG; Song SH; Park WB; Park SW; Kim NJ; Oh MD
J Korean Med Sci; 2020 Jun; 35(24):e231. PubMed ID: 32567262
[TBL] [Abstract][Full Text] [Related]
33. Uncertainty about the Efficacy of Remdesivir on COVID-19.
Yoo JH
J Korean Med Sci; 2020 Jun; 35(23):e221. PubMed ID: 32537956
[No Abstract] [Full Text] [Related]
34. Drug treatments for covid-19: living systematic review and network meta-analysis.
Siemieniuk RA; Bartoszko JJ; Zeraatkar D; Kum E; Qasim A; Martinez JPD; Izcovich A; Lamontagne F; Han MA; Agarwal A; Agoritsas T; Azab M; Bravo G; Chu DK; Couban R; Devji T; Escamilla Z; Foroutan F; Gao Y; Ge L; Ghadimi M; Heels-Ansdell D; Honarmand K; Hou L; Ibrahim Q; Khamis A; Lam B; Mansilla C; Loeb M; Miroshnychenko A; Marcucci M; McLeod SL; Motaghi S; Murthy S; Mustafa RA; Pardo-Hernandez H; Rada G; Rizwan Y; Saadat P; Switzer C; Thabane L; Tomlinson G; Vandvik PO; Vernooij RW; Viteri-García A; Wang Y; Yao L; Zhao Y; Guyatt GH; Brignardello-Petersen R
BMJ; 2020 Jul; 370():m2980. PubMed ID: 32732190
[TBL] [Abstract][Full Text] [Related]
35. Advance of promising targets and agents against COVID-19 in China.
Duan Y; Zhu HL; Zhou C
Drug Discov Today; 2020 May; 25(5):810-812. PubMed ID: 32198066
[No Abstract] [Full Text] [Related]
36. Remdesivir, lopinavir, emetine, and homoharringtonine inhibit SARS-CoV-2 replication in vitro.
Choy KT; Wong AY; Kaewpreedee P; Sia SF; Chen D; Hui KPY; Chu DKW; Chan MCW; Cheung PP; Huang X; Peiris M; Yen HL
Antiviral Res; 2020 Jun; 178():104786. PubMed ID: 32251767
[TBL] [Abstract][Full Text] [Related]
37. Have we found the panacea to COVID-19 with remdesivir, an old but newly packaged drug?
Thalha AMM; Lee YY; Besari A; Omar SFS
J R Coll Physicians Edinb; 2020 Jun; 50(2):159-161. PubMed ID: 32568289
[No Abstract] [Full Text] [Related]
38. Update on recommendations for the diagnosis and treatment of SARS-CoV-2 infection in children.
Miao H; Li H; Yao Y; Wu M; Lu C; Wang J; Tian M; Li Y; Luo P; Gu J; Yuan B; Wang S; Zhao X; Gan W; Zhao D
Eur J Clin Microbiol Infect Dis; 2020 Dec; 39(12):2211-2223. PubMed ID: 32761481
[TBL] [Abstract][Full Text] [Related]
39. A comparative analysis of remdesivir and other repurposed antivirals against SARS-CoV-2.
Simonis A; Theobald SJ; Fätkenheuer G; Rybniker J; Malin JJ
EMBO Mol Med; 2021 Jan; 13(1):e13105. PubMed ID: 33015938
[TBL] [Abstract][Full Text] [Related]
40. Effect of remdesivir on patients with COVID-19: A network meta-analysis of randomized control trials.
Yokoyama Y; Briasoulis A; Takagi H; Kuno T
Virus Res; 2020 Oct; 288():198137. PubMed ID: 32827627
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]